Bristol's hepatitis C combo shows high cure rates in trial

04/10/2014 | Reuters

A late-stage trial showed Bristol-Myers Squibb's hepatitis C combination therapy daclatasvir and asunaprevir cured 90% of previously untreated patients with genotype 1b virus after 24 weeks of therapy. The drug also cured 82% of patients who couldn't tolerate interferon and ribavirin, the older standard treatments for the disease. "Not only was the daclatasvir and asunaprevir regimen highly effective among study participants, it was also very well tolerated, even among sicker patients with more advanced liver disease," lead investigator Michael Manns said. The drug combo has already been submitted for FDA review.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY